The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Lasofoxifene in Postmenopausal Women with Osteoporosis
Open accessAbstract
BACKGROUND: The effects of lasofoxifene on the risk of fractures, breast cancer, and cardiovascular disease are uncertain. METHODS: In this randomized trial, we assigned 8556 women who were between the ages of 59 and 80 years and had a bone mineral density T score of -2.5 or less at the femoral neck or spine to receive once-daily lasofoxifene (at a dose of either 0.25 mg or 0.5 mg) or placebo for 5 years. Primary end points were vertebral fractures, estrogen receptor (ER)-positive breast cancer, and nonvertebral fractures; secondary end points included major coronary heart disease events and stroke. RESULTS: Lasofoxifene at a dose of 0.5 mg per day, as compared with placebo, was associated with reduced risks of vertebral fracture (13.1 cases vs. 22.4 cases per 1000 person-years; hazard ratio, 0.58; 95% confidence interval [CI], 0.47 to 0.70), nonvertebral fracture (18.7 vs. 24.5 cases per 1000 person-years; hazard ratio, 0.76; 95% CI, 0.64 to 0.91), ER-positive breast cancer (0.3 vs. 1.7 cases per 1000 person-years; hazard ratio, 0.19; 95% CI, 0.07 to 0.56), coronary heart disease events (5.1 vs. 7.5 cases per 1000 person-years; hazard ratio, 0.68; 95% CI, 0.50 to 0.93), and stroke (2.5 vs. 3.9 cases per 1000 person-years; hazard ratio, 0.64; 95% CI, 0.41 to 0.99). Lasofoxifene at a dose of 0.25 mg per day, as compared with placebo, was associated with reduced risks of vertebral fracture (16.0 vs. 22.4 cases per 1000 person-years; hazard ratio, 0.69; 95% CI, 0.57 to 0.83) and stroke (2.4 vs. 3.9 cases per 1000 person-years; hazard ratio, 0.61; 95% CI, 0.39 to 0.96) Both the lower and higher doses, as compared with placebo, were associated with an increase in venous thromboembolic events (3.8 and 2.9 cases vs. 1.4 cases per 1000 person-years; hazard ratios, 2.67 [95% CI, 1.55 to 4.58] and 2.06 [95% CI, 1.17 to 3.60], respectively). Endometrial cancer occurred in three women in the placebo group, two women in the lower-dose lasofoxifene group, and two women in the higher-dose lasofoxifene group. Rates of death per 1000 person-years were 5.1 in the placebo group, 7.0 in the lower-dose lasofoxifene group, and 5.7 in the higher-dose lasofoxifene group. CONCLUSIONS: In postmenopausal women with osteoporosis, lasofoxifene at a dose of 0.5 mg per day was associated with reduced risks of nonvertebral and vertebral fractures, ER-positive breast cancer, coronary heart disease, and stroke but an increased risk of venous thromboembolic events. (ClinicalTrials.gov number, NCT00141323.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Hulley, S. (1998) · JAMA · doi:10.1001/jama.280.7.605 · Cited by 6,216
Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.18.1371 · Cited by 5,485
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067312 · Cited by 2,986
Self-citationCummings, S. R. (1998) · JAMA · doi:10.1001/jama.280.24.2077 · Cited by 2,277
Self-citationCummings, S. R., Eckert, S., Krueger, K. A., Grady, D., Powles, T. J., Cauley, J. A., Norton, L., Nickelsen, T., Bjarnason, N. H., Morrow, M., et al. (1999) · JAMA · doi:10.1001/jama.281.23.2189 · Cited by 1,872
Self-citationReginster, J. Y., Seeman, E., De Vernejoul, M. C., Adami, S., Compston, J., Phenekos, C., Devogelaer, J. P., Curiel, M. D., Sawicki, A., Goemaere, S., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1774 · Cited by 1,071
Stone, K. L., Seeley, D. G., Lui, L.-Y., Cauley, J. A., Ensrud, K., Browner, W. S., Nevitt, M. C., & Cummings, S. R. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.11.1947 · Cited by 1,051
Self-citationEffects of Raloxifene on Cardiovascular Events and Breast Cancer in Postmenopausal Women
Barrett-Connor, E., Mosca, L., Collins, P., Geiger, M. J., Grady, D., Kornitzer, M., McNabb, M. A., & Wenger, N. K. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062462 · Cited by 1,048
Cummings, S. R. (1999) · Medical Entomology and Zoology · Cited by 797
Self-citationMartino, S., Cauley, J. A., Barrett-Connor, E., Powles, T. J., Mershon, J., Disch, D., Secrest, R. J., Cummings, S. R., & For the CORE Investigators (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh319 · Cited by 684
Self-citationCauley, J. A., Norton, L., Lippman, M. E., Eckert, S., Krueger, K. A., Purdie, D. W., Farrerons, J., Karasik, A., Mellstrom, D., Ng, K. W., et al. (2001) · Breast Cancer Research and Treatment · doi:10.1023/a:1006478317173 · Cited by 678
Self-citationGenant, H. K., Jergas, M., Palermo, L., Nevitt, M., Valentin, R. S., Black, D., & Cummings, S. R. (1996) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650110716 · Cited by 643
Self-citationBarrett-Connor, E., Grady, D., Sashegyi, A., Anderson, P. W., Cox, D. A., Hoszowski, K., Rautaharju, P., Harper, K. D., & for the MORE Investigators (2002) · JAMA · doi:10.1001/jama.287.7.847 · Cited by 577
Cuzick, J., Forbes, J. F., Sestak, I., Cawthorn, S., Hamed, H., Holli, K., & Howell, A. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk049 · Cited by 534
Wells, G. A., Cranney, A., Peterson, J., Boucher, M., Shea, B., Welch, V., Coyle, D., & Tugwell, P. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003376.pub3 · Cited by 499
The Effects of Tibolone in Older Postmenopausal Women
Cummings, S. R., Ettinger, B., Delmas, P. D., Kenemans, P., Stathopoulos, V., Verweij, P., Mol-Arts, M., Kloosterboer, L., Mosca, L., Christiansen, C., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800743 · Cited by 457
Self-citationPowles, T. J., Ashley, S., Tidy, A., Smith, I. E., & Dowsett, M. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk050 · Cited by 430
Self-citationHigh-Trauma Fractures and Low Bone Mineral Density in Older Women and Men
Mackey, D. C. (2007) · JAMA · doi:10.1001/jama.298.20.2381 · Cited by 352
Walsh, B. W., Paul, S., Wild, R. A., Dean, R. A., Tracy, R. P., Cox, D. A., & Anderson, P. W. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.1.6326 · Cited by 326
Land, S. R., Wickerham, D. L., Costantino, J. P., Ritter, M. W., Vogel, V. G., Lee, M., Pajon, E. R., Wade, J. L., Dakhil, S., Lockhart, J. B., et al. (2006) · JAMA · doi:10.1001/jama.295.23.joc60075 · Cited by 238
McCloskey, E. V., Beneton, M., Charlesworth, D., Kayan, K., de Takats, D., Dey, A., Orgee, J., Ashford, R., Forster, M., Cliffe, J., et al. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.061008 · Cited by 200
Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation
Felson, D. T., & Cummings, S. R. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21364 · Cited by 162
Self-citationWalsh, B. W. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.1.214 · Cited by 143
The postmenopausal estrogen/progestin interventions study: primary outcomes in adherent women
Barrett-Connor, E. L., Slone, S. A., Greendale, G. A., Kritz‐Silverstein, D. C., Espeland, M. A., Johnson, S. R., Waclawiw, M. A., & Fineberg, S. E. (1997) · Maturitas · doi:10.1016/s0378-5122(97)00041-8 · Cited by 130
Safety assessment of raloxifene over eight years in a clinical trial setting
Martino, S., Disch, D. P., Dowsett, S. A., Keech, C. A., & Mershon, J. L. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x61839 · Cited by 113
Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene
McClung, M. R., Siris, E. S., Cummings, S., Bolognese, M. A., Ettinger, M. P., Moffett, A. H., Emkey, R. D., Day, W. W., Somayaji, V. R., & Lee, A. (2006) · Menopause The Journal of The North American Menopause Society · doi:10.1097/01.gme.0000188736.69617.4f · Cited by 111
Self-citationSelective Estrogen Receptor Modulators for Postmenopausal Osteoporosis: Current State of Development
Gennari, L., Merlotti, D., Valleggi, F., Martini, G., & Nuti, R. (2007) · Drugs & Aging · doi:10.2165/00002512-200724050-00002 · Cited by 109
Cited by
Estrogens and androgens in skeletal physiology and pathophysiology
Almeida, M., Laurent, M. R., Dubois, V., Claessens, F., O'Brien, C. A., Bouillon, R., Vanderschueren, D., & Manolagas, S. C. (2017) · Physiological Reviews · doi:10.1152/physrev.00033.2015 · Cited by 860
Eastell, R., O'Neill, T. W., Hofbauer, L. C., Langdahl, B., Reid, I. R., Gold, D. T., & Cummings, S. R. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.69 · Cited by 827
Self-citationPrevention and treatment of postmenopausal osteoporosis
Tella, S. H., & Gallagher, J. C. (2014) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2013.09.008 · Cited by 786
Patel, H. K., & Bihani, T. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.12.012 · Cited by 499
Cuzick, J., Sestak, I., Bonanni, B., Costantino, J. P., Cummings, S., DeCensi, A., Dowsett, M., Forbes, J. F., Ford, L., LaCroix, A. Z., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60140-3 · Cited by 495
Self-citation
Metadata
- Authors
- Cummings, S. R., Ensrud, K., Delmas, P. D., LaCroix, A. Z., Vukicevic, S., Reid, D. M., Goldstein, S., Sriram, U., Lee, A., Thompson, J., Armstrong, R. A., Thompson, D. D., Powles, T., Zanchetta, J., Kendler, D., Neven, P., & Eastell, R.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-02-25
- Volume
- 362
- Issue
- 8
- Pages
- 686-696
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2103829266
- Cited by
- 387
- References
- 32
- FWCI
- 36.33
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.